**Ebola Treatment Trial Begins in DR Congo Amid Ongoing Outbreak**
A clinical trial aimed at evaluating two potential treatments for Ebola has commenced in the Democratic Republic of the Congo (DR Congo), where the current outbreak has claimed nearly 440 lives, as reported by the World Health Organization (WHO). The trial, known as the Platform Adaptive Randomized Trial for New and Repurposed Filovirus TreatmentS (PARTNERS), was announced by WHO Director-General Tedros Adhanom Ghebreyesus on Thursday, with the enrollment of the first participant.
As of now, the WHO has confirmed 1,406 cases of the Bundibugyo strain of the Ebola virus, which is known for its high infectivity. This strain currently lacks both approved vaccines and specific treatments, making the need for effective therapeutic options urgent. "We urgently need treatments that can help people affected by Bundibugyo virus disease," stated Professor Amanda Rojek, the PARTNERS Trial Operations Lead. She emphasized the importance of conducting research in parallel with outbreak response efforts, rather than waiting until after the crisis has passed.
The trial is being conducted in collaboration with several partners, including the DR Congo’s National Institute of Biomedical Research, Oxford University, and the Antwerp Institute of Tropical Medicine. The study will assess the efficacy of Gilead Sciences’ antiviral drug remdesivir and Mapp Biopharmaceutical’s MBP134, an antibody-based treatment. Participants will receive standard care while being monitored for survival over a 28-day period.
The WHO declared a public health emergency of international concern in May, following laboratory confirmations of Bundibugyo virus disease in both DR Congo and Uganda. This outbreak marks the 17th occurrence of Ebola in DR Congo since the virus was first identified in 1976. Uganda has reported 20 confirmed cases and two fatalities related to the outbreak. Additionally, France recently recorded its first case of Ebola, involving a doctor who returned from a humanitarian mission in DR Congo.
The Africa Centers for Disease Control and Prevention (Africa CDC) highlighted the significant strain on health systems in DR Congo, particularly in Ituri Province, which is the epicenter of the outbreak. Ongoing conflict and violence in regions such as Ituri, North Kivu, and South Kivu have exacerbated humanitarian conditions, leading to mass displacement and increased vulnerability among the population.
Africa CDC Director-General Jean Kaseya indicated that approximately $1.4 billion is needed to effectively respond to the Ebola outbreak, a figure that is three times higher than previous estimates. This financial requirement underscores the challenges faced by health authorities in managing the outbreak and providing adequate care to affected individuals.
As the trial progresses, health officials and researchers remain hopeful that the findings will contribute to the development of effective treatments for the Bundibugyo strain of Ebola, ultimately helping to mitigate the impact of this deadly virus in the region.